Vera Therapeutics Launches TRUTAKNA, Widens Loss on Commercial Buildout
Vera Therapeutics posted a net loss of $109.5 million for the second quarter as it began commercial launch of its newly approved kidney-disease drug TRUTAKNA.
Vera Therapeutics (VERA) began commercial sales of TRUTAKNA (atacicept-vymj) after the drug received FDA accelerated approval for adult IgA nephropathy patients at risk of disease progression, marking the biotechnology company's transition from a clinical-stage developer to a commercial-stage one.
The approval, TRUTAKNA's first for any indication, arrived as the company reported a net loss of $109.5 million, or $1.52 a share, for the second quarter of 2026, up 43% from a loss of $76.5 million, or $1.20 a share, a year earlier. The widening loss reflected spending to prepare for the launch rather than a deterioration in the drug's clinical profile.
General and administrative expense rose nearly 2.4 times over the year to $52.4 million in the quarter from $21.9 million, as Vera built out commercial infrastructure ahead of TRUTAKNA's approval. Research and development spending held roughly flat at $60.1 million versus $58.2 million a year earlier, so the increase in total operating expenses, which rose 40% to $112.5 million from $80.1 million, was driven by commercial preparation rather than the pipeline.
The launch spending showed up most directly in the balance sheet. Cash, cash equivalents and marketable securities fell to $499.2 million as of June 30 from $714.6 million at the end of 2025, a drawdown of roughly $215 million over two quarters. Six-month net cash used in operating activities roughly doubled to $206.8 million from $109.2 million in the first half of 2025. Vera also disclosed up to $425 million newly available under a debt facility, subject to conditions, giving it additional capacity as the cash burn accelerates.
Share count grew alongside the spending, with weighted-average diluted shares outstanding rising to 71.8 million from 63.8 million a year earlier, about 12.6% dilution.
Vera laid out a forward timeline tied to TRUTAKNA's regulatory path. The company expects a final efficacy analysis from its ORIGIN 3 trial in the third quarter of 2026, ahead of its previous expectation, aligned with the FDA, followed by a supplemental biologics license application submission in the fourth quarter. Additional results from the PIONEER program are also expected in the fourth quarter, with potential full approval targeted for 2027.
The company also disclosed a leadership change, naming Nancy Boman, M.D., Ph.D. as Chief Regulatory Officer, succeeding William Turner, who moves to a role as Strategic Advisor in the third quarter of 2026.
Vera's next quarters will show whether the commercial buildout translates into TRUTAKNA revenue that offsets the wider losses and cash draw, with the ORIGIN 3 and PIONEER readouts due before year-end setting up the case for full approval in 2027.